Premier Research and Centogene N.V. announced a strategic partnership to provide end-to-end support in rare disease clinical trials. The collaboration aims to improve patient identification, stratification, recruitment, and enrollment, thereby increasing the likelihood of study success. With 350 million rare disease patients worldwide affected by over 7,000 rare diseases, approximately 95% of which do not have an available treatment, there is a pressing need to accelerate trials and fast-track clinical outcomes.

Inherently small patient populations coupled with the complexities of disease diagnosis create significant challenges in enrolling rare disease clinical trial participants. Combining Premier Research's deep expertise in rare disease product development with advanced insights generated from the CENTOGENE Biodatabank and multiomic reference laboratories will support the faster identification of eligible patients. Premier Research is constantly investing in new approaches that meet the complexities of rare disease research.

Like Premier Research, CENTOGENE has a history of success in rare diseases, offering rapid and reliable molecular diagnoses since 2006 while building a network of approximately 30,000 active physicians worldwide. The Company's ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is then captured in the CENTOGENE Biodatabank which currently contains nearly 700,000 patients representing over 120 highly diverse countries, more than 70% of whom are of non- European descent including a large share of pediatric cases.